Although many industries and jobs have been heavily impacted by the COVID-19 pandemic, pharma R&D jobs were the least affected when compared to other sectors.
According to Randstad Sourceright’s U.S. COVID-19 talent impact analysis report, which analyzed new job postings across various industries and data from the Bureau of Labor Statistics, job postings related to pharmaceutical R&D only decreased by 17% during March and April — the smallest drop of any job function analyzed in the report.
“Not shocking and not surprising was the fact that the pharma industry was the industry that really stood out as having the least impact,” said Sue Marcus, regional president for Randstad Sourceright North America.
In fact, as pharmaceutical firms continue working to develop a coronavirus vaccine, demand for clinical trial research associates and clinical trial managers saw a 46 percent increase.
Marcus also predicted that the demand for clinical trial professionals will remain stable, as some businesses and functions that have been put on hold due to COVID-related clinical trials will “start to get back to their normal pace and priority” when the pandemic is over.
Read the full article in Triangle Business Journal for additional insights hiring pharmaceutical and clinical trial professionals. You can also get your exclusive copy of “How is key talent in the US impacted by COVID-19?” for a full analysis of COVID-19’s impact on six job families, including customer service, engineering, finance, pharma R&D, sales and software development.
About the AuthorMore Content by Sue Marcus